Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967
Conditions
Interventions
Carboplatin
Pegylated liposomal doxorubicin (PLD)
+3 more
Locations
19
Germany
Charite Campus Virchow Klinikum
Berlin, Germany
Städtische Klinikum Dessau
Dessau, Germany
Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden
Dresden, Germany
Evangelische Kliniken-Essen-Mitte
Essen, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Mammazentrum HH am Krankenhaus Jerusalem
Hamburg, Germany
Start Date
October 13, 2021
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2026
Last Updated
April 6, 2025
Lead Sponsor
AGO Research GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions